BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28545165)

  • 21. Profiling of three H3F3A-mutated and denosumab-treated giant cell tumors of bone points to diverging pathways during progression and malignant transformation.
    Hasenfratz M; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Roitman PD; Aponte-Tinao LA; Lehner B; Möller P; Mechtersheimer G; Barth TFE
    Sci Rep; 2021 Mar; 11(1):5709. PubMed ID: 33707617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The identification of H3F3A mutation in giant cell tumour of the clivus and the histological diagnostic algorithm of other clival lesions permit the differential diagnosis in this location.
    Scotto di Carlo F; Divisato G; Iacoangeli M; Esposito T; Gianfrancesco F
    BMC Cancer; 2018 Apr; 18(1):358. PubMed ID: 29609578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic and molecular features of denosumab-treated giant cell tumour of bone (GCTB): Analysis of 21 cases.
    Yang L; Zhang H; Zhang X; Tang Y; Wu Z; Wang Y; Huang H; Fu X; Liu J; Hogendoorn PCW; Cheng H
    Ann Diagn Pathol; 2022 Apr; 57():151882. PubMed ID: 34995868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Globally altered epigenetic landscape and delayed osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone.
    Lutsik P; Baude A; Mancarella D; Öz S; Kühn A; Toth R; Hey J; Toprak UH; Lim J; Nguyen VH; Jiang C; Mayakonda A; Hartmann M; Rosemann F; Breuer K; Vonficht D; Grünschläger F; Lee S; Schuhmacher MK; Kusevic D; Jauch A; Weichenhan D; Zustin J; Schlesner M; Haas S; Park JH; Park YJ; Oppermann U; Jeltsch A; Haller F; Fellenberg J; Lindroth AM; Plass C
    Nat Commun; 2020 Oct; 11(1):5414. PubMed ID: 33110075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Knock-down of oncohistone H3F3A-G34W counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells.
    Fellenberg J; Sähr H; Mancarella D; Plass C; Lindroth AM; Westhauser F; Lehner B; Ewerbeck V
    Cancer Lett; 2019 Apr; 448():61-69. PubMed ID: 30742944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature.
    Ratnagiri R; Uppin S
    J Cancer Res Ther; 2023; 19(3):832-834. PubMed ID: 37470622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of
    Luo Y; Tang J; Huang J; Hu D; Bai Y; Chen J; Sun K; Zhang H; Liu Z
    J Bone Oncol; 2023 Feb; 38():100467. PubMed ID: 36619849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases.
    Koelsche C; Schrimpf D; Tharun L; Roth E; Sturm D; Jones DTW; Renker EK; Sill M; Baude A; Sahm F; Capper D; Bewerunge-Hudler M; Hartmann W; Kulozik AE; Petersen I; Flucke U; Schreuder HWB; Büttner R; Weber MA; Schirmacher P; Plass C; Pfister SM; von Deimling A; Mechtersheimer G
    Clin Sarcoma Res; 2017; 7():9. PubMed ID: 28484590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Giant cell tumor of bone: updated molecular pathogenesis and tumor biology.
    Noh BJ; Park YK
    Hum Pathol; 2018 Nov; 81():1-8. PubMed ID: 29944971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic lockdown of CDKN1A (p21) and CDKN2A (p16) characterises the neoplastic spindle cell component of giant cell tumours of bone.
    Giesche J; Mellert K; Geißler S; Arndt S; Seeling C; von Baer A; Schultheiss M; Marienfeld R; Möller P; Barth TF
    J Pathol; 2022 Aug; 257(5):687-696. PubMed ID: 35522566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
    Behjati S; Tarpey PS; Presneau N; Scheipl S; Pillay N; Van Loo P; Wedge DC; Cooke SL; Gundem G; Davies H; Nik-Zainal S; Martin S; McLaren S; Goodie V; Robinson B; Butler A; Teague JW; Halai D; Khatri B; Myklebost O; Baumhoer D; Jundt G; Hamoudi R; Tirabosco R; Amary MF; Futreal PA; Stratton MR; Campbell PJ; Flanagan AM
    Nat Genet; 2013 Dec; 45(12):1479-82. PubMed ID: 24162739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of Three Novel H3F3A-mutated Giant Cell Tumor Cell Lines and Targeting of Their Wee1 Pathway.
    Lübbehüsen C; Lüke J; Seeling C; Mellert K; Marienfeld R; von Baer A; Schultheiss M; Möller P; Barth TFE
    Sci Rep; 2019 Apr; 9(1):6458. PubMed ID: 31015476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of H3F3A p.G35W and p.G35R in giant cell tumor of bone by Allele Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR).
    Gamberi G; Morandi L; Benini S; Resca A; Cocchi S; Magagnoli G; Donati DM; Righi A; Gambarotti M
    Pathol Res Pract; 2018 Jan; 214(1):89-94. PubMed ID: 29254795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach.
    Kervarrec T; Collin C; Larousserie F; Bouvier C; Aubert S; Gomez-Brouchet A; Marie B; Miquelestorena-Standley E; Le Nail LR; Avril P; Christophe Pagès J; de Pinieux G
    Mod Pathol; 2017 Mar; 30(3):393-406. PubMed ID: 28059095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.
    Venneker S; Szuhai K; Hogendoorn PCW; Bovée JVMG
    Virchows Arch; 2020 Jan; 476(1):135-146. PubMed ID: 31728625
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotypic and molecular differences between giant-cell tumour of soft tissue and its bone counterpart.
    Mancini I; Righi A; Gambarotti M; Picci P; Dei Tos AP; Billings SD; Simi L; Franchi A
    Histopathology; 2017 Sep; 71(3):453-460. PubMed ID: 28477388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reliability and Role of Mutation-specific H3F3A (Histone 3-3) G34W Immunohistochemistry to Differentiate Giant Cell Tumor of Bone From its Clinicoradiologic and Histologic Mimics: An Institutional Study.
    Pasricha S; Pruthi M; Jajodia A; Kumar A; Gupta G; Sharma A; Tiwari A; Rohela H; Durga G; Kamboj M; Koyyala VPB; Mehta A
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):36-41. PubMed ID: 34347625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of Histone H3.3 (G34W)-Mutant Protein in Pathological Diagnosis of Giant Cell Tumor of Bone.
    Miskad UA; Syamsul F; Dahlan H; Sungowati NK; Achmad D; Johan MP
    Asian Pac J Cancer Prev; 2023 May; 24(5):1737-1741. PubMed ID: 37247296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.
    Ishihara S; Yamamoto H; Iwasaki T; Toda Y; Yamamoto T; Yoshimoto M; Ito Y; Susuki Y; Kawaguchi K; Kinoshita I; Yamada Y; Kohashi K; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Kakuda Y; Nakashima Y; Oda Y
    Mod Pathol; 2022 May; 35(5):640-648. PubMed ID: 34785767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Giant-cell-poor giant cell tumor of bone: report of two cases and literature review.
    Yakoub MA; Torrence D; Hwang S; Bartelstein M; Healey JH; Hameed M
    Skeletal Radiol; 2023 Sep; 52(9):1791-1798. PubMed ID: 36781420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.